Robotic versus laparoscopic surgery for rectal cancer: a comparative cost-effectiveness study.

Cost–benefit analysis Health care costs Laparoscopy Quality-adjusted life years Rectal neoplasms Robotic surgical procedures

Journal

Techniques in coloproctology
ISSN: 1128-045X
Titre abrégé: Tech Coloproctol
Pays: Italy
ID NLM: 9613614

Informations de publication

Date de publication:
03 2020
Historique:
received: 24 09 2019
accepted: 17 01 2020
pubmed: 6 2 2020
medline: 28 4 2021
entrez: 6 2 2020
Statut: ppublish

Résumé

The differences between the costs of robotic rectal resection and of the laparoscopic approach are still not well known. The aim of this study was to evaluate the cost-effectiveness of robotic versus laparoscopic surgery. We conducted an observational, comparative, prospective, non-randomized study on patients having laparoscopic and robotic rectal resection between February 2014 and March 2018 at the Sanchinarro University Hospital, Madrid. Outcome parameters included surgical and post-operative costs, quality adjusted life years (QALY) and incremental cost per QALY gained or the incremental cost effectiveness ratio (ICER). The primary endpoint was to compare cost effectiveness in the robotic and laparoscopic surgery groups. A willingness-to-pay of 20,000€ and 30,000€ per QALY was used as a threshold to determine the most cost-effective treatment. A total of 81 RRR and 104 LRR were included. The mean operative costs were higher for RRR (4307.09€ versus 3834.58€; p = 0.04), although mean overall costs were similar (7272.03€ for RRR and 6968.63€ for the LLR; p = 0.44). Mean QALYs at 1 year for the RRR group (0.8482) was higher than that associated with LRR (0.6532) (p = 0.018). At a willingness-to-pay threshold of 20,000€ and 30,000€ there was a 95.54% and 97.18% probability, respectively, that RRR was more cost-effective than LRR. Our data regarding the cost-effectiveness of RRR versus LRR shows a benefit for RRR.

Sections du résumé

BACKGROUND
The differences between the costs of robotic rectal resection and of the laparoscopic approach are still not well known. The aim of this study was to evaluate the cost-effectiveness of robotic versus laparoscopic surgery.
METHODS
We conducted an observational, comparative, prospective, non-randomized study on patients having laparoscopic and robotic rectal resection between February 2014 and March 2018 at the Sanchinarro University Hospital, Madrid. Outcome parameters included surgical and post-operative costs, quality adjusted life years (QALY) and incremental cost per QALY gained or the incremental cost effectiveness ratio (ICER). The primary endpoint was to compare cost effectiveness in the robotic and laparoscopic surgery groups. A willingness-to-pay of 20,000€ and 30,000€ per QALY was used as a threshold to determine the most cost-effective treatment.
RESULTS
A total of 81 RRR and 104 LRR were included. The mean operative costs were higher for RRR (4307.09€ versus 3834.58€; p = 0.04), although mean overall costs were similar (7272.03€ for RRR and 6968.63€ for the LLR; p = 0.44). Mean QALYs at 1 year for the RRR group (0.8482) was higher than that associated with LRR (0.6532) (p = 0.018). At a willingness-to-pay threshold of 20,000€ and 30,000€ there was a 95.54% and 97.18% probability, respectively, that RRR was more cost-effective than LRR.
CONCLUSIONS
Our data regarding the cost-effectiveness of RRR versus LRR shows a benefit for RRR.

Identifiants

pubmed: 32020350
doi: 10.1007/s10151-020-02151-7
pii: 10.1007/s10151-020-02151-7
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

247-254

Références

Int J Colorectal Dis. 2017 Oct;32(10):1423-1429
pubmed: 28791457
Eur J Health Econ. 2013 Jun;14(3):367-72
pubmed: 23526140
Gac Sanit. 2005 Mar-Apr;19(2):135-50
pubmed: 15860162
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Int J Med Robot. 2014 Sep;10(3):300-5
pubmed: 24692203
Eur J Health Econ. 2010 Oct;11(5):513-20
pubmed: 20405159
Int J Colorectal Dis. 2016 Sep;31(9):1639-48
pubmed: 27475091
Dis Colon Rectum. 2012 Oct;55(10):1017-23
pubmed: 22965399
Tech Coloproctol. 2017 May;21(5):355-361
pubmed: 28560480
Surg Endosc. 2018 Apr;32(4):2106-2113
pubmed: 29067582
World J Surg. 2012 Nov;36(11):2722-9
pubmed: 22855217
Surg Endosc. 2014 Jan;28(1):212-21
pubmed: 23996335
Asian J Surg. 2018 Sep;41(5):401-416
pubmed: 28912048
JAMA. 2017 Oct 24;318(16):1569-1580
pubmed: 29067426
World J Gastrointest Oncol. 2014 Jun 15;6(6):184-93
pubmed: 24936229
Trials. 2018 Jun 27;19(1):339
pubmed: 29945673
Medicine (Baltimore). 2017 Jul;96(29):e7585
pubmed: 28723798
PLoS One. 2018 Jan 23;13(1):e0191628
pubmed: 29360840

Auteurs

Y Quijano (Y)

Department of General Surgery, Hospital Universitario HM Sanchinarro, HM Hospitales, Madrid, Spain.

J Nuñez-Alfonsel (J)

Instituto de Validación de La Eficiencia Clínica (IVEc), Fundación de Investigación HM Hospitales, Madrid, Spain. jnalfonsel@fundacionhm.com.

B Ielpo (B)

Department of General Surgery, Hospital HM Regla, HM Hospitales, León, Spain.

V Ferri (V)

Department of General Surgery, Hospital Universitario HM Sanchinarro, HM Hospitales, Madrid, Spain.

R Caruso (R)

Department of General Surgery, Hospital Universitario HM Sanchinarro, HM Hospitales, Madrid, Spain.

H Durán (H)

Department of General Surgery, Hospital Universitario HM Sanchinarro, HM Hospitales, Madrid, Spain.

E Díaz (E)

Department of General Surgery, Hospital Universitario HM Sanchinarro, HM Hospitales, Madrid, Spain.

L Malavé (L)

Department of General Surgery, Hospital Universitario HM Sanchinarro, HM Hospitales, Madrid, Spain.

I Fabra (I)

Department of General Surgery, Hospital Universitario HM Sanchinarro, HM Hospitales, Madrid, Spain.

E Pinna (E)

Department of General Surgery, Hospital Universitario HM Sanchinarro, HM Hospitales, Madrid, Spain.

R Isernia (R)

Department of General Surgery, Hospital Universitario HM Sanchinarro, HM Hospitales, Madrid, Spain.

Á Hidalgo (Á)

Department of Economic Analysis and Finances, University of Castilla-La Mancha, Toledo, Spain.

E Vicente (E)

Department of General Surgery, Hospital Universitario HM Sanchinarro, HM Hospitales, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH